The Global Microbiome Therapeutics Market is valued at USD 125.1 Million in 2022 and is expected to reach USD 1065.7 Million by 2029 with a CAGR of 35.8% over the forecast period.
Global Microbiome Therapeutics Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Increasing prevalence of C. Difficile infection, rising clinical trials in microbiome therapeutics, and growing research and developments strategies are major factors anticipated to drive the growth of the Global Microbiome Therapeutics Market within the Forecast Period.
Microbiome refers to the entire collection of genes from all microorganisms, including parasites, bacteria, archaea, fungi, and viruses, which live in or on many parts of the body, including the skin, eyes, and gut. These microbes are generally not harmful; 80% of them are in fact beneficial. Microbiome therapeutics are used for disease management. With the help of technology, the human gut microbiome is used as a therapeutic for disease management. Microbiome therapy has a great potential to treat any severe type of disease condition. Microbiome therapeutics have no side effects, as microbes are normal residents within the body that increase their therapeutic capacity without any side effects. Furthermore, microbes can be genetically engineered to enhance their effectiveness and safety.
The Covid-19 pandemic has had a mixed impact on the microbiome therapeutics market. On one hand, the increased focus on immune health during the pandemic has led to a growing interest in the role of the microbiome in overall health and disease prevention. This has created new opportunities for microbiome-based therapies, including those targeting Covid-19 and related conditions. On the other hand, disruptions to clinical trials and supply chains have delayed the development and commercialization of some microbiome-based therapies. Additionally, the economic impact of the pandemic has led to budget constraints for some healthcare providers and patients, which may impact the demand for and accessibility of these therapies. Overall, the long-term impact of the Covid-19 pandemic on the microbiome therapeutics market remains to be seen, but it is expected to continue to grow due to the increasing recognition of the importance of the microbiome in human health.
Global air freshener market is segmented based on type, application, and region & country level. Based on type, the air freshener market is segmented into FMT (Fecal Microbiota Transplant) and microbiome drugs. Based on application, the air freshener market is segmented into C. difficile, Crohn’s disease, inflammatory bowel disease, diabetes and others.
The regions covered in global microbiome therapeutics market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global microbiome therapeutics market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
Some of the key players for global microbiome therapeutics market are -
One of the major factors driving the market growth of global microbiome therapeutics is the increasing prevalence of C. difficile infection. Fecal microbiota transplant has shown a great success rate in the treatment of patients with recurrent C. difficile infection. Thus, the growing prevalence of the condition is expected to heighten the demand for microbiome therapies. For instance; as per the Center for Disease Control and Prevention, C. difficile is projected to cause almost half a million infections in the United States each year.
In addition, rising number of clinical trials in microbiome therapeutics are also supplementing the market growth. For instance; a purified preparation of stool bacteria known as SER-109 had met its primary end point in a phase 3 trial and shown a reduced risk of recurrent gastrointestinal infection by 30%, as the pathogenic bacterium Clostridium difficile by more than 30% reported by Seres Therapeutics. On August 10th, 2020, and in 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III data of their candidate RBX2660 for the reduction in recurrent C. difficile infection. Hence, clinical trials like these in microbiome therapeutics and improvements in microbiome research are anticipated to support the finding of better treatments for infections and boosting the market growth.
Moreover, growing research and development strategies are also fostering the market growth. Partnerships and merger and acquisition strategies adopted by players for the development of innovative microbiome therapeutics are also supplementing the market's growth. For instance; on November 10th, 2022; EnteroBiotix partnered with Imperial College London to develop microbiome therapeutics. These research activities are supporting the future growth of the global microbiome therapeutics market.
However, the proper identification of disease-causing microbial signatures and lack of consideration of ethical and safety issues may restrain the growth of the global microbiome therapeutics market. In spite of that, research and development activities in this field may offer future opportunities for the further growth of global microbiome therapeutics market.
North America is expected to dominate the global microbiome therapeutics market due to its highly developed healthcare infrastructure, research and development activities, and the development of novel therapeutics in this region. The highly developed healthcare infrastructure in North America is supporting the growth of the microbiome therapeutics market in this region. In addition, research and development activities are also boosting the market growth. For instance; an open call for 2021 US research grant applications was given to the Biocodex Microbiota Foundation, and $50,000 was granted for research in gut microbiota and its impact beyond the digestive system. These R&D investments are fueling the microbiome therapeutics market in this region.
Asia Pacific is expected to be the fastest growing region for the global microbiome therapeutics market due to developing healthcare facilities and rising investments in microbiome therapeutics research in this region. For example; Cykinsco (Tokyo) received 270 million yen from the Regional Health Care Industry Support Fund to develop an intestinal flora test.
MyBiotics Pharma Received Investment from Mii Fund, an Innovator in the Field of Dermatology
In February 3rd, 2021; MyBiotics announced an investment from Mii Fund, as well as a partnership with Maruho Co. Ltd., Japan's preeminent leader in dermatology, on February 3rd, 2021. MyBiotics will use the funds to advance its microbiome therapeutics pipeline and endure to improve its unique microbiome platform technologies.
|2016 - 2021
|2022 - 2029
|Market Size in 2022:
|USD 125.1 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2029:
|USD 1065.7 Million
|Tables, Charts & Figures:
|4D Pharma, AOBiome, Hansen, DuPont Nutrition & Biosciences, Evelo Biosciences, Ferring Pharmaceuticals, Microbiome Therapeutics LLC, Osel, Rebiotix, Second Genome, Seres Therapeutics, Synlogic, Synthetic Biologics, Vedanta Biosciences, Yakult Honsha Co., Ltd., Others.
|By Type, By Application
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®